Posted on 1/25/18
Johnson & Johnson Down Small on Huge Loss -- What Gives?
On this episode of the Market Foolery podcast, Chris Hill chats with Jim Mueller from Stock Advisor and Motley Fool Options and Abi Malin of Hidden . . .
Posted on 1/25/18
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today . . .
Posted on 1/24/18
Johnson & Johnson: Buy The 1st 4% Drop Since March 2009
Johnson & Johnson (JNJ) reported earnings yesterday morning and beat estimates on both the top and bottom line, but shares traded down over 4%. The decline . . .
Posted on 1/24/18
Celgene (CELG) Announces Acquisition Of Juno Therapeutics - Slideshow
The following slide deck was published by Celgene Corporation in conjunction with this event. 125READ FULL ARTICLE HERE
Posted on 1/24/18
How To Trade Johnson & Johnson After Slump On U.S. Tax Charges
Johnson & Johnson (JNJ) opened Tuesday at $146.96 after trading as high as $151.00 pre-market on an initial positive reaction to earnings. The open was below . . .
Posted on 1/24/18
Celgene's Investments Are Soaring
Celgene Corp.'s (NASDAQ:CELG) acquiring its collaboration partner, Juno Therapeutics, for $9 billion, and that's fueling investor interest in Celgene's other collaboration partners. bluebird bio (NASDAQ:BLUE), Jounce . . .
Posted on 1/24/18
Tax Losses Mask Johnson & Johnson's Fundamental Strength
Tax reform has been a hot-button issue with corporate America during the current earnings season, and as one of the largest multinational conglomerates in the world, . . .
Posted on 1/24/18
Strongbridge Biopharma Announces Proposed Public Offering of 5 Million Ordinary Shares
DUBLIN, Ireland and TREVOSE, Pa., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that it intends to offer and sell 5 million . . .
Posted on 1/24/18
Johnson & Johnson's (JNJ) CEO Alex Gorsky on Q4 2017 Results - Earnings Call Transcript
Hello. I am Joe Walk, Vice President of Investor relations for Johnson & Johnson. Welcome to our company’s review of business results for the fourth quarter . . .
Posted on 1/23/18
Incyte Recommends Shareholders Reject Mini-Tender Offer by TRC Capital
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) today announced that it received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to 1,500,000 . . .
Posted on 1/23/18
Johnson & Johnson: What's About To Happen?
Article thesisJohnson & Johnson (JNJ) reports fourth quarter results on Tuesday and has a good chance of beating estimates again. Due to consistent growth, great diversification . . .
Posted on 1/23/18
Merck Has Strong Conviction In KalVista's Phase 2 Clinical Trial Of KVD001 In DME
BackgroundKalVista Pharmaceuticals (KALV) is a clinical-stage pharmaceutical company focused on the development of small molecule protease inhibitors. The company is still in its infancy and market . . .
Posted on 1/23/18
Whom Will Pfizer Buy in 2018?
It's going to happen.I have no doubt that Pfizer (NYSE:PFE) will make a significant acquisition this year. After a couple of notable deals in 2016, the . . .
Posted on 1/23/18
Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?
It's now official.Reports generated excitement last week that Celgene (NASDAQ:CELG) planned to buy out Juno Therapeutics (NASDAQ:JUNO). Neither company commented on the rumors then. But Monday . . .
Posted on 1/23/18
Insmed Announces Proposed Public Offering of Convertible Senior Notes
BRIDGEWATER, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $300 million aggregate principal . . .
Posted on 1/22/18
Marinus Pharma's Ganaxolone: If At First You Don't Succeed...
Marinus has steadfastly tested ganaxolone in many areas despite failing in its first P3 study.The company is currently testing ganaxolone in three areas and has other . . .
Posted on 1/22/18
Pfizer: The Best Big Pharma Dividend Stock
Pfizer (PFE) has long been one of my favorite pharmaceutical stocks. The last 5 years haven't been the best given an aging portfolio, but performance appears . . .
Posted on 1/22/18
Will This Tiny Biotech Be Celgene's Next Takeover Target?
Rumors are swirling that Celgene Corp (NASDAQ:CELG) is considering a multibillion-dollar acquisition of Juno Therapeutics (NASDAQ:JUNO). That got me thinking: What other companies could be on . . .
Posted on 1/22/18
3 Biotech Stocks That Soared This Week: Are They Buys?
You know it's a good week when a stock in your portfolio soars 28%. Actually, good is probably an understatement. But that's exactly what three biotech . . .
Posted on 1/22/18
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
Your time horizon makes a huge difference when choosing between which stocks to buy. For example, suppose it's January 2011, and you're trying to decide between . . .
Posted on 1/22/18
Quest Diagnostics Named One of 2018 "World's Most Admired Companies" by Fortune Magazine for Third Consecutive Year
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" . . .
Posted on 1/19/18
What's Juno Therapeutics Worth to Celgene?
Celgene Corp. (NASDAQ:CELG) owns ex-U.S. rights to Juno Therapeutics' (NASDAQ:JUNO)lead drug, liso-cel (formerly JCAR017), and it owns nearly 10% of Juno Therapeutics' stock, yet that may . . .
Posted on 1/19/18
Healthcare: Is Celgene Going to Buy Juno Therapeutics?
Rumors are swirling that Celgene Corp. (NASDAQ:CELG) may pay billions of dollars to buy Juno Therapeutics (NASDAQ:JUNO) lock, stock, and barrel. Do these rumors make sense?In . . .
Posted on 1/18/18
U.S. Patent Office Invalidates Key Patent Covering J&J's Cancer Drug Zytiga
Generic encroachment on Johnson & Johnson's (NYSE:JNJ) top-selling cancer drug Zytiga (abiraterone) is a step closer after the USPTO's Patent Trial and Appeal Board invalidated a . . .
Posted on 1/18/18
Johnson & Johnson Aims to Start 2018 Healthy
Johnson & Johnson (NYSE:JNJ) had a strong 2017, with its stock posting a nearly 25% total return. Key moves like the acquisitions of Actelion and Abbott . . .

